Avalo Therapeutics (AVTX) Cash from Investing Activities (2016 - 2026)
Avalo Therapeutics' (AVTX) quarterly Cash from Investing Activities came in at $25.5 million in Q1 2026, up 962.27% on a QoQ basis from $2.4 million in Q4 2025.
Powered by 
Analysis
Avalo Therapeutics (AVTX) Cash from Investing Activities (2016 - 2026) Analysis & Trends
Avalo Therapeutics (AVTX) has 11 years of Cash from Investing Activities data on file, last reported at $25.5 million in Q1 2026.
- Quarterly Cash from Investing Activities changed N/A year-over-year to $25.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$56.2 million (changed N/A YoY) and the FY2025 annual result came in at -$81.7 million, down 23055.06% from the prior year.
- Cash from Investing Activities climbed to $25.5 million in Q1 2026, from $2.4 million in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $25.5 million in Q1 2026 to a low of -$70.9 million in Q2 2025.
- A 5-year average of -$7.0 million and a median of -$47500.0 in 2022 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2022 — Cash from Investing Activities jumped 51.85% — and 2024, when it surged 367.67%.
- Tracing AVTX's Cash from Investing Activities over 5 years: stood at -$39000.0 in 2022, then plunged by 241.03% to -$133000.0 in 2023, then surged by 367.67% to $356000.0 in 2024, then surged by 574.44% to $2.4 million in 2025, then surged by 962.27% to $25.5 million in 2026.
- The last three Cash from Investing Activities figures came in at $25.5 million (Q1 2026), $2.4 million (Q4 2025), and -$13.3 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 329.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -1.66 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -49.35 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -363.46 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -229.72 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 24.51 Mn |
| 10 | Avalo Therapeutics | 843.26 Mn | 843.26 Mn | - | -329.93 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -329.93 Mn |
| Mar 31, 2026 | 25.51 Mn |
| Dec 31, 2025 | 2.40 Mn |
| Sep 30, 2025 | -13.26 Mn |
| Jun 30, 2025 | -70.86 Mn |
| Mar 31, 2024 | 356,000.00 |
| Mar 31, 2023 | -133,000.00 |
| Sep 30, 2022 | -39,000.00 |
| Jun 30, 2022 | -56,000.00 |
| Dec 31, 2021 | -11,000.00 |
| Sep 30, 2021 | -81,000.00 |
| Mar 31, 2021 | -21,000.00 |
| Dec 31, 2020 | -391,000.00 |
| Sep 30, 2020 | -63,000.00 |
| Jun 30, 2020 | 12.84 Mn |
| Mar 31, 2020 | -1.25 Mn |
| Dec 31, 2019 | -180,991.00 |
| Sep 30, 2019 | -5,085.00 |
| Jun 30, 2019 | -90,957.00 |
| Mar 31, 2019 | -165,969.00 |